Therapeutic | Zenocutuzumab |
Target 1 | ERBB3 |
Heavy Chain 1 | QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDHGSRHFWSYWGFDYWGQGTLVTVSS |
Light Chain 1 | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK |
100% seqID Fv 1 Structure | 5o4o [Fvs: BA], 5o7p [Fvs: BA] |
99% seqID Fv 1 Structure | None |
95-98% seqID Fv 1 Structure | None |
Target 2 | ERBB2 |
Heavy Chain 2 | QVQLVQSGAEVKKPGASVKLSCKASGYTFTAYYINWVRQAPGQGLEWIGRIYPGSGYTSYAQKFQGRATLTADESTSTAYMELSSLRSEDTAVYFCARPPVYYDSAWFAYWGQGTLVTVSS |
Light Chain 2 | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK |
100% seqID Fv 2 Structure | 5o4g [Fvs: BA] |
99% seqID Fv 2 Structure | None |
95-98% seqID Fv 2 Structure | None |
100% seqID Structure [Fv 1] | 5o4o [Fvs: BA] |
100% seqID Structure [Fv 1] | 5o7p [Fvs: BA] |
100% seqID Structure [Fv 2] | 5o4g [Fvs: BA] |
Follow these links to our prediction tools:
Format | Bispecific mAb |
Isotype | G1 |
Highest Clinical Trial (Jan '20) | Phase-II |
Estimated Status (Jan '20) | Active |
Recorded Developmental Technology | GlymaxX Technology |
INN Year Proposed | 2017 |
INN Year Recommended | 2018 |
Companies Involved | Merus |
Conditions Approved | na |
Conditions Active | Breast cancer, Colorectal cancer, Gastric cancer, Non-small cell lung cancer |
Conditions Discontinued | Endometrial cancer, Ovarian cancer |
Notes |